• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by HOOKIPA Pharma Inc.

    6/20/23 11:04:27 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HOOK alert in real time by email
    SC 13G 1 tm2319096d1_sc13g.htm SC 13G

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549
     
    SCHEDULE 13G*
    (Rule 13d-102)
     
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
    PURSUANT TO RULE 13d-2
    (Amendment No. __)*
     
      Hookipa Pharma Inc.  
    (Name of Issuer)
     
      COMMON STOCK, PAR VALUE $0.0001 PER SHARE  
    (Title of Class of Securities)
     
    43906K100
    (CUSIP Number)

     

      May 31, 2023  
    (Date of Event Which Requires Filing of the Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)
    xRule 13d-1(c)
    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)

     

     

     

     

     

     

    Cusip No.

    43906K100_______________

    13G Page 2 of 8 Pages

     

    1. 

    NAME OF REPORTING PERSONS

     

    Knoll Capital Management, LLC 

    2. 

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) 

    (a)      ¨

    (b)     x

    3.

    SEC USE ONLY

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Florida

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    5,517,385

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    5,517,385

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 

     

    5,517,385 

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ¨

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.8%

     

    12.

     

    TYPE OF REPORTING PERSON

     

    LLC

     

     

     Page 2 of 8 

     

     

    Cusip No.

    43906K100_______________

    13G Page 3 of 8 Pages

     

    1. 

    NAME OF REPORTING PERSONS

     

    Fred Knoll

    2. 

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) 

    (a)      ¨

    (b)     x

    3.

    SEC USE ONLY

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    USA

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    5,517,385

     

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    5,517,385

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 

     

    5,517,385 

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ¨

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.8%

     

    12.

     

    TYPE OF REPORTING PERSON

     

    IN

     

     

     Page 3 of 8 

     

     

    Cusip No.

    43906K100_______________

    13G Page 4 of 8 Pages

     

    1. 

    NAME OF REPORTING PERSONS

     

    Gakasa Holdings, LLC

    2. 

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) 

    (a)      ¨

    (b)     x

    3.

    SEC USE ONLY

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Florida

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    5,517,385

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    5,517,385

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 

     

    5,517,385 

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ¨

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.8%

     

    12.

     

    TYPE OF REPORTING PERSON

     

    LLC

     

     

     Page 4 of 8 

     

     

    Cusip No.

    43906K100_______________

    13G Page 5 of 8 Pages

     

    Item 1(a).Name of Issuer:

     

    Hookipa Pharma Inc. (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    350 Fifth Ave, 72nd Floor, Suite 7240, New York NY 10118

     

    Item 2(a).Name of Persons Filing:

     

    Knoll Capital Management LLC (“KCM”)

    Fred Knoll (“Knoll”)

    Gakasa Holdings, LLC. (“Gakasa”)

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    The principle business address for each of KCM, Knoll and Gakasa is 201 S. Biscayne Blvd suite 800, Miami, FL 33131

     

    Item 2(c).Citizenship:

     

    KCM is a limited liability company formed and existing under the laws of the State of Florida.

    Knoll is a citizen of the United States.

    Gakasa is a limited liability company organized under the laws of the State of Florida.

     

    Item 2(d).Title of Class of Securities:

     

    Common shares par value 0.0001 per share ("Ordinary Shares")

     

    Item 2(e).CUSIP Number:

     

    43906K100

     

    Item 3.If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: Not applicable

     

    (a) ¨Broker or dealer registered under Section 15 of the Act (15 U.S.C 78o);
         
    (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C 78c);
         
    (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C 78c);
         
    (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
         
    (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
         
    (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
         
    (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
         
    (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
         
    (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
         
    (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: _________________

     

     Page 5 of 8 

     

     

    Cusip No.

    43906K100 _______________

    13G Page 6 of 8 Pages

     

    Item 4.Ownership:

     

    Provide the following information regarding the aggregate number and percentage of class of securities of the issuer identified in Item 1.

     

    (a)Amount beneficially owned:

     

    As of this filing: Gakasa beneficially owns 5,517,385 Shares of the Issuer’s Common Stock. Each of KCM and Knoll beneficially own 5,517,385 Shares of the Issuer’s Common Stock. KCM has trading authority for Gakasa, and Knoll is the President of KCM.

     

    (b)Percent of Class:

     

    The shares of the Issuer’s Common Stock beneficially owned by each of Gakasa, KCM and Knoll constitute 6.8% of the Issuer’s Common Stock outstanding.

     

    This percentage is calculated based on 81,600,000 shares of common stock outstanding as per company guidance.

      

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: 0

     

    (ii)shared power to vote or to direct the vote: 5,517,385

     

    KCM, Knoll and Gakasa share the power to vote or direct the vote of those shares of Common Stock owned by Gakasa.

     

    (iii)sole power to dispose or to direct the disposition of: 0

     

    (iv)shared power to dispose or to direct the disposition of: 5,517,385

     

    KCM, Knoll and Gakasa share the power to dispose of or direct the disposition of those shares of Common Stock owned by Gakasa.

     

    Item 5.Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person:

     

    Not Applicable.

     

     Page 6 of 8 

     

     

    Cusip No.

    43906K100 _______________

    13G Page 7 of 8 Pages

     

     

    Item 7.Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group:

     

    Not Applicable.

     

    Item 9.Notice of Dissolution of Group:

     

    Not Applicable

     

    Item 10.Certifications:

     

    By Signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 7 of 8 

     

     

    Cusip No.

    43906K100 _______________

    13G Page 8 of 8 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, I certify (the undersigned certifies) that the information set forth in this statement is true, complete and correct.

     

      KNOLL CAPITAL MANAGEMENT, LLC.
       
      By: /s/ Fred Knoll
    Dated: June 16, 2023 Name: Fred Knoll
      Title: President
       
      /s/ Fred Knoll
    Dated: June 16, 2023 Fred Knoll
       
      GAKASA HOLDINGS, LLC.
      By: Knoll Capital Management, LLC.
       
      By: /s/ Fred Knoll
    Dated: June 16, 2023 Name: Fred Knoll
    Title: President

     

     Page 8 of 8 

     

     

    Get the next $HOOK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HOOK

    DatePrice TargetRatingAnalyst
    12/20/2024$48.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    11/15/2024$50.00 → $48.00Outperform
    RBC Capital Mkts
    12/2/2022Neutral → Underperform
    BofA Securities
    2/17/2022$15.00 → $8.00Buy
    HC Wainwright & Co.
    2/16/2022$3.00 → $4.00Outperform
    SVB Leerink
    11/12/2021$6.00Overweight → Equal-Weight
    Morgan Stanley
    11/11/2021$21.00 → $15.00Buy
    HC Wainwright & Co.
    11/10/2021$28.00 → $10.00Outperform
    SVB Leerink
    More analyst ratings

    $HOOK
    SEC Filings

    View All

    SEC Form 15-12G filed by HOOKIPA Pharma Inc.

    15-12G - HOOKIPA Pharma Inc. (0001760542) (Filer)

    8/8/25 12:48:05 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by HOOKIPA Pharma Inc.

    EFFECT - HOOKIPA Pharma Inc. (0001760542) (Filer)

    7/30/25 12:15:02 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by HOOKIPA Pharma Inc.

    EFFECT - HOOKIPA Pharma Inc. (0001760542) (Filer)

    7/30/25 12:15:05 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOOK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Peters Malte sold $20,684 worth of shares (25,172 units at $0.82), decreasing direct ownership by 32% to 54,347 units (SEC Form 4)

    4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)

    10/9/25 4:22:11 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Peters Malte sold $26,842 worth of shares (29,176 units at $0.92), decreasing direct ownership by 27% to 79,519 units (SEC Form 4)

    4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)

    7/23/25 6:09:44 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP and CFO Coelho Mary Theresa sold $12,520 worth of shares (13,609 units at $0.92), decreasing direct ownership by 19% to 56,266 units (SEC Form 4)

    4 - HOOKIPA Pharma Inc. (0001760542) (Issuer)

    7/23/25 6:07:41 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOOK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics

    NEW YORK and VIENNA, Austria, Feb. 03, 2026 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, "HOOKIPA", the "Company") today announced the sale of its immuno-oncology related assets, consisting primarily of the HB-200 (eseba-vec) and HB-700 development programs, to NeoTrail Therapeutics, Inc. ("NeoTrail"). The purchase price remains undisclosed. "We are delighted that the clinical development of these promising therapeutics will continue at NeoTrail with an opportunity to deliver patient benefit in multiple major market indications," stated Mark Winderlich, Chief R&D Officer of HOOKIPA. The asset purchase agreement was signed on January 28, 2026, and the transaction is expected to c

    2/3/26 8:30:00 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead

    NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, "HOOKIPA") today announced the completion of the sale of its assets related to HOOKIPA's HB-400 program and certain of its assets related to HOOKIPA's HB-500 program to Gilead Sciences, Inc. ("Gilead"). In connection with the consideration and evaluation of HOOKIPA's long-term prospects and strategies by HOOKIPA's board of directors, on May 21, 2025 HOOKIPA entered into an asset purchase agreement ("Asset Purchase Agreement") with Gilead pursuant to which Gilead agreed to acquire all of HOOKIPA's assets primarily related to or necessary for the conduct of HOOKIPA's HB-400 program, currently in clinica

    10/31/25 8:00:00 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock

    NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA")), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced its intention to voluntarily delist from the Nasdaq Capital Market ("Nasdaq") and to deregister its common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and suspend its reporting obligations under Section 15(d) of the Exchange Act. In connection with the consideration and evaluation of HOOKIPA's long-term prospects and strategies by HOOKIPA's board of dire

    7/18/25 4:05:00 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOOK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HOOKIPA Pharma downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded HOOKIPA Pharma from Outperform to Sector Perform and set a new price target of $2.00 from $48.00 previously

    12/20/24 7:37:05 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts reiterated coverage on HOOKIPA Pharma with a new price target

    RBC Capital Mkts reiterated coverage of HOOKIPA Pharma with a rating of Outperform and set a new price target of $48.00 from $50.00 previously

    11/15/24 11:07:50 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma downgraded by BofA Securities

    BofA Securities downgraded HOOKIPA Pharma from Neutral to Underperform

    12/2/22 12:03:07 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOOK
    Leadership Updates

    Live Leadership Updates

    View All

    HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates

    Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule SITC 2024 late-breaking poster highlights Phase 2 eseba-vec data updates for increased number of patients reflecting ORR and durability in line with prior data First patients dosed in Phase 2 investigator led study with MSKCC in new clinical setting as adjuvant therapy for head and neck cancer Strength of HB-700 KRAS-inhibitor program highlighted by preclinical dataset presented at recent RAS Targeted Drug Development Summit NEW YORK and VIENNA, Austria, Nov. 14, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")

    11/14/24 4:05:00 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma Announces Board of Directors Changes

    NEW YORK and VIENNA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Director Julie O'Neill as Non-Executive Chair of the Company's Board of Directors. She succeeds Jan van de Winkel, who has decided to step down from the Board effective August 30, 2024, due to increasing time commitments from his executive position as Chief Executive Officer of Genmab A/S. The Company also announced that Tim Reilly has chosen to step down from the Board, also effective August 30th, to be able to dedicate more time to his o

    8/30/24 8:00:00 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

    New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 "AVALON-1" study with eseba-vec in Q4 2024 ASCO 2024 Presentation:   Reported best-in-class Phase 2 data for first-line HPV16+ head and neck cancer patients treated with eseba-vec (formerly HB-200) in combination with pembrolizumab during oral presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual MeetingRegulatory Progress:   Announced alignment with U.S. Food and Drug Administration (FDA) for the AVALON-1 Phase 2/3 pivotal trial design and protocol for eseba-vec, in combination with pembrolizumab for the first-li

    8/8/24 4:30:00 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOOK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by HOOKIPA Pharma Inc.

    SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

    11/14/24 6:07:08 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by HOOKIPA Pharma Inc.

    SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

    8/2/24 6:38:55 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by HOOKIPA Pharma Inc.

    SC 13G - HOOKIPA Pharma Inc. (0001760542) (Subject)

    7/8/24 6:51:26 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HOOK
    Financials

    Live finance-specific insights

    View All

    HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting

    Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumabIn a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company's selected registrational pivotal trial population, data showed confirmed ORR of 53%, CR rate of 18%, and DCR of 82%Preliminary progression-free survival (PFS) was 16.3 months and preliminary overall survival (OS) rate was 88% at 9 months for the CPS 20 or higher subgroup, comparing favorably to current standard of careCompany will host a conference call at 4:15 p.m. ET today NEW YORK and VIENNA, June 04, 2024 (GLOBE NEWSWIRE) -- H

    6/4/24 1:00:44 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

    Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for oral abstract presentation at ASCO 2024 Annual Meeting with data from approximately 40 patients treated with HB-200 in combination with pembrolizumab Two additional abstracts for HB-200 and HB-700 accepted for the ASCO 2024 Annual Meeting Company to host investor call at 8:00 a.m. ET on Thursday, April 25, 2024, to highlight path to potential registration; participant details below NEW YORK and VIENNA, Austria, April 25, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDA

    4/25/24 7:01:00 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023

    NEW YORK and VIENNA, Austria, Nov. 02, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release its third quarter 2023 financial results and business highlights on November 9, 2023. The company will not be conducting a conference call in conjunction with this financial release. About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ:HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight o

    11/2/23 4:01:00 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care